(Reuters) -Zimmer Biomet Holdings on Monday lowered its full-year adjusted profit forecast, as the medical device maker anticipates a hit from its recent acquisition of Paragon 28, currency volatility, and proposed tariffs. Investors and analysts are closely monitoring how medical device makers will handle any impact from the Trump administration's tariffs and whether they expect benefits from foreign currency fluctuations. Earlier this year, Zimmer said that it would acquire medical device firm Paragon 28 for $1.1 billion, to expand its portfolio of orthopedic surgical devices. Zimmer expects 2025 adjusted profit per share in the range of $7.90 to $8.10, compared with its prior view of $8.15 to $8.35 per share. Analysts were expecting annual profit of $8.19 per share, according to data compiled by LSEG. The Warsaw, Indiana-based company expects currency swings to have a negligible to marginally positive effect on its 2025 revenue, revising its initial forecast of a 1.5% to 2% negative impact to a range of 0% to 0.5%. Last week, peer Stryker Corp reduced its 2025 profit outlook and said it anticipated a $200 million tariff impact in the year. However, Zimmer's first-quarter profit and revenue both came in slightly above expectations, due to strong demand for its devices used in hip and knee procedures. Combined sales at Zimmer's hips and knees units came in at $1.29 billion, compared to $1.28 billion, a year ago. On an adjusted basis, the company posted a profit of $1.81 per share for the quarter ended March 31, topping estimates of $1.77 per share. Zimmer's first-quarter revenue came in at $1.91 billion, slightly ahead of estimates of $1.90 billion. (Reporting by Kamal Choudhury in Bengaluru; Editing by Shailesh Kuber) View Comments
Zimmer Biomet lowers 2025 profit forecast on acquisition costs, tariff uncertainty
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...